Patrick Bergstedt, Senior Vice President of Moderna, visited Taiwan for the first time.

(Photo by reporter Wu Liangyi)

[Reporter Wu Liangyi/Report from Taipei] Vaccine manufacturer Moderna announced yesterday that it will cooperate with eight domestic medical centers to conduct human trials of mRNA influenza vaccine.

Taiwan is the only country in Asia where Moderna has cooperated in human trials of mRNA influenza-like vaccines. It is expected that trial data will be released in March next year. In the future, Moderna's mRNA technology platform will also be opened to researchers around the world.

The senior vice president praised my medical and biological skills

Moderna set up a branch in Taiwan this year, and held a press conference yesterday. Patrick Bergstedt, the global senior vice president of Moderna who visited Taiwan for the first time, praised that Taiwan’s COVID-19 vaccine coverage rate exceeds 80%, which is the highest among countries all over the world. Extremely rare.

Moreover, Taiwan respects intellectual property rights, has a world-class medical care system, diverse industrial talents, scientists and research institutions, and is world-renowned for its biotechnology innovation capabilities.

Please read on...

In addition, Taiwan is the first country in the Asia-Pacific region to pass BA.1 and BA.4/5 bivalent next-generation vaccines. In the future, Moderna will continue to cooperate with the Taiwan government and develop partnerships to increase vaccine supply and epidemic prevention resilience. .

Open mRNA technology platform for global use

Patrick Bergstedt said that Moderna is expanding its public health product portfolio to promote mRNA technology and vaccines to combat existing and emerging infectious diseases, targeting the World Health Organization (WHO) and the Coalition for Epidemic Prevention Innovations (CEPI) by 2025 ) Kuang listed the 15 pathogens with the most public health risks in the world, and made every effort to develop vaccines and enter the clinical trial stage.

In addition to the new coronavirus, the fifteen kinds of pathogens include the familiar Ebola, HIV, MERS, Mycobacterium tuberculosis, etc., as well as the less common Nipah virus, Marburg virus, Crimean Congo hemorrhagic fever and Rift Valley fever Wait.

In addition, the second priority is "mRNA Access", which plans to open the Moderna mRNA technology platform to global researchers including Taiwan, and gather global professionals to conduct research on emerging and neglected infectious diseases.

Patrick Bergstedt said that he will also visit the Ministry of Health and Welfare during his trip, hoping to maintain a partnership with Taiwan in the future.

Moderna set up a branch in Taiwan in September this year. Li Yizhen, general manager of Taiwan, said that in addition to making influenza vaccines, there are also human respiratory fusion virus (RSV), etc., to strengthen the research on vaccines for respiratory infectious diseases.

The next focus is to bring the latest mRNA medicine into the Taiwan market, continue to strive for Taiwan to join the multi-center clinical research program, and start the talent recruitment plan.

However, for the medical center-level hospitals to be cooperated at this stage, Moderna stated that it is still in the research and development stage, and the details cannot be disclosed to the public.